Shares of Corbus Pharmaceuticals CRBP fell 1.3% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were flat 0.00% year over year to ($0.43), which missed the estimate of ($0.40).
Revenue of $1,762,000 lower by 6.57% from the same period last year, which missed the estimate of $2,410,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 11, 2020
Time: 08:00 PM ET
Webcast URL: https://78449.themediaframe.com/dataconf/productusers/crbp/mediaframe/37399/indexl.html
Price Action
Company's 52-week high was at $7.99
Company's 52-week low was at $3.29
Price action over last quarter: Up 62.16%
Company Description
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
